SolAeroMed

SolAeroMed develops novel therapeutic strategies and medical devices for respiratory healthcare, with a lead candidate S‑1226™ targeting acute severe asthma. The company also provides contract research services and co-develops/co-markets two medical devices. Their main drug candidate offers a new bronchodilator mechanism distinct from existing treatments like Salbutamol/Albuterol. Additional pipeline assets include preclinical work in cystic fibrosis and previously investigated COVID‑19 therapies, though the latter appears to be suspended. The company operates primarily out of Cambridge, MA, USA, with historical ties to Calgary, Alberta.